…does PYC - the peptide biotech - have the scientific capability to make its own ASOs?
According to Rohan Hockings, yes.
My notes from the investor call have it mentioned twice.
Early in the call, Rohan mentioned that PYC has built capacity in-house to develop the ASO cargo. Alternatively, PYC could in-license the cargo or out-license the CPP to other parties, which he said would be done if it didn’t own the IP.
Further in the call, in answer to a question about whether the cargo would be in-licensed, he said that it was possible, but that it was also possible for PYC to design its own cargo.
The Whole Molecule, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.0¢ | $415.6K | 3.255M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 112056 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 127118 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |